← Back to Search

Cytokine

Pembrolizumab for Renal Cell Carcinoma

Phase 1
Waitlist Available
Led By Scott S. Tykodi
Research Sponsored by University of Washington
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at baseline and every 3 months
Awards & highlights

Summary

This trial is testing the side effects and best dose of aldesleukin when given with pembrolizumab to treat patients with kidney cancer.

Eligible Conditions
  • Renal Cell Carcinoma
  • Kidney Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at baseline and every 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline and every 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of adverse events
Secondary study objectives
Anti-tumor activity
Change in performance status
Disease control rate (DCR)
+2 more
Other study objectives
Absolute numbers of effector T cells (Teff)
Absolute numbers of regulatory T cells (Treg)
Chromosomal copy number alterations
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (pembrolizumab, aldesleukin)Experimental Treatment2 Interventions
Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Patients also receive aldesleukin subcutaneously (SC) 5 days per week for 6 weeks; or aldesleukin IV on days 2-6 of pembrolizumab cycles 1 and 2. Pembrolizumab treatment repeats every 3 weeks for 4 cycles per treatment course in the absence of clinical disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
2017
Completed Phase 3
~2850
Aldesleukin
2012
Completed Phase 4
~1620

Find a Location

Who is running the clinical trial?

University of WashingtonLead Sponsor
1,801 Previous Clinical Trials
1,908,844 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
3,960 Previous Clinical Trials
5,176,531 Total Patients Enrolled
Prometheus LaboratoriesIndustry Sponsor
26 Previous Clinical Trials
4,790 Total Patients Enrolled
~1 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top